关注
Javier Puente Vazquez
Javier Puente Vazquez
Medical Oncology Department, Hospital Clinico San Carlos, Madrid
在 salud.madrid.org 的电子邮件经过验证
标题
引用次数
引用次数
年份
Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant …
TM Beer, ED Kwon, CG Drake, K Fizazi, C Logothetis, G Gravis, V Ganju, ...
Journal of Clinical Oncology 35 (1), 40-47, 2017
7402017
PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer
E Castro, N Romero-Laorden, A Del Pozo, R Lozano, A Medina, J Puente, ...
Journal of Clinical Oncology 37 (6), 490-503, 2019
3392019
Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables
J Sastre, ML Maestro, J Puente, S Veganzones, R Alfonso, S Rafael, ...
Annals of Oncology 19 (5), 935-938, 2008
2972008
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre …
J Garcia-Donas, E Esteban, LJ Leandro-García, DE Castellano, ...
The lancet oncology 12 (12), 1143-1150, 2011
2872011
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution …
V Conteduca, D Wetterskog, MTA Sharabiani, E Grande, ...
Annals of Oncology 28 (7), 1508-1516, 2017
2742017
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial
C Sweeney, S Bracarda, CN Sternberg, KN Chi, D Olmos, S Sandhu, ...
The Lancet 398 (10295), 131-142, 2021
2242021
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
R Rosell, U Dafni, E Felip, A Curioni-Fontecedro, O Gautschi, S Peters, ...
The Lancet Respiratory Medicine 5 (5), 435-444, 2017
2162017
Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer
KN Chi, D Rathkopf, MR Smith, E Efstathiou, G Attard, D Olmos, JY Lee, ...
Journal of Clinical Oncology 41 (18), 3339-3351, 2023
1472023
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial
MR Smith, HI Scher, S Sandhu, E Efstathiou, PN Lara, YY Evan, ...
The Lancet Oncology 23 (3), 362-373, 2022
1292022
Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma
C Prior, JL Perez-Gracia, J Garcia-Donas, C Rodriguez-Antona, ...
PloS one 9 (1), e86263, 2014
1032014
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: a randomized trial
P Vink, I Delgado Mingorance, C Maximiano Alonso, B Rubio‐Viqueira, ...
Cancer 125 (8), 1301-1312, 2019
1002019
Learning-based scheduling of flexible manufacturing systems using ensemble methods
P Priore, B Ponte, J Puente, A Gómez
Computers & Industrial Engineering 126, 282-291, 2018
942018
Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer
M Martin, A Romero, MCU Cheang, JA López García-Asenjo, ...
Breast cancer research and treatment 128, 127-136, 2011
932011
Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma
J Garcia-Donas, LJ Leandro-Garcia, AG Del Alba, M Morente, I Alemany, ...
Annals of oncology 24 (9), 2409-2414, 2013
882013
Plasma androgen receptor and docetaxel for metastatic castration-resistant prostate cancer
V Conteduca, A Jayaram, N Romero-Laorden, D Wetterskog, S Salvi, ...
European urology 75 (3), 368-373, 2019
812019
Solving multi-objective rescheduling problems in dynamic permutation flow shop environments with disruptions
P Valledor, A Gomez, P Priore, J Puente
International Journal of Production Research 56 (19), 6363-6377, 2018
642018
Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting
J Puente, E Grande, A Medina, P Maroto, N Lainez, JA Arranz
Therapeutic advances in medical oncology 9 (5), 307-318, 2017
612017
DUTRENEO Trial: A randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC …
E Grande, F Guerrero, J Puente, I Galante, I Duran, M Dominguez, ...
Journal of Clinical Oncology 38 (15_suppl), 5012-5012, 2020
582020
Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer
JA García-Sáenz, M Martín, J Puente, S López-Tarruella, A Casado, ...
Clinical breast cancer 6 (4), 325-329, 2005
572005
¿ Qué es el cáncer y cómo se desarrolla
J Puente, G de Velasco
Sociedad Española de Oncología Médica (SEOM), 2019
552019
系统目前无法执行此操作,请稍后再试。
文章 1–20